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Abstract
Background: Decisions about interim analysis and early stopping of clinical trials, as based on
recommendations of Data Monitoring Committees (DMCs), have far reaching consequences for
the scientific validity and clinical impact of a trial. Our aim was to evaluate the frequency and quality
of the reporting on DMC composition and roles, interim analysis and early termination in pediatric
trials.
Methods: We conducted a systematic review of randomized controlled clinical trials published
from 2005 to 2007 in a sample of four general and four pediatric journals. We used full-text
databases to identify trials which reported on DMCs, interim analysis or early termination, and
included children or adolescents. Information was extracted on general trial characteristics, risk of
bias, and a set of parameters regarding DMC composition and roles, interim analysis and early
termination.
Results: 110 of the 648 pediatric trials in this sample (17%) reported on DMC or interim analysis
or early stopping, and were included; 68 from general and 42 from pediatric journals. The presence
of DMCs was reported in 89 of the 110 included trials (81%); 62 papers, including 46 of the 89 that
reported on DMCs (52%), also presented information about interim analysis. No paper adequately
reported all DMC parameters, and nine (15%) reported all interim analysis details. Of 32 trials
which terminated early, 22 (69%) did not report predefined stopping guidelines and 15 (47%) did
not provide information on statistical monitoring methods.
Conclusions: Reporting on DMC composition and roles, on interim analysis results and on early
termination of pediatric trials is incomplete and heterogeneous. We propose a minimal set of
reporting parameters that will allow the reader to assess the validity of trial results.
Background
Data Monitoring Committees (DMCs) are central to mod-
ern clinical trials. They play a critical role in safeguarding
both the interests of study participants and the scientific
integrity of randomized trials[1] This task is performed
through interim monitoring of safety and efficacy out-
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come data, as well as vigilance over the conduct of the
study and safety aspects/adverse events. One of the key
activities of DMCs is to make recommendations to the
sponsor or steering committee regarding the appropriate-
ness of trial continuation. Thus, the recommendations of
a DMC can influence the conclusion and interpretation of
trial results and, indirectly, their implementation in clini-
cal practice.
Experts and regulators have recently published recom-
mendations for the appointment and operational proce-
dures of DMCs [1-5] The increasing use and visibility of
DMCs has fostered research into their activities[6] There is
evidence of heterogeneity in their roles and policies [7-9]
The wide range of interim monitoring methods that are
available entails considerable variability in DMCs' risk-
benefit evaluations[1,2,10] These issues are relevant as the
analyses and decisions made by DMCs may be controver-
sial and can influence study validity, particularly in the
case of trials terminated early [11-14]
Assessing DMCs' recommendations requires adequate
reporting of their activities and considerations. Previous
studies have suggested that reporting is insufficient for
various subsets of publications and types of trials[8,11,15-
18] The CONSORT statement of reporting guidelines for
clinical trials includes an item on interim analysis, but no
details on a DMCs' activities and considerations are
required[19]
There is consensus that DMCs should be a standard
requirement for trials with vulnerable populations, such
as children[1,4,5,7,20-22] In a recent review of pediatric
trials performed until 2002, only 2% of the trials were
reported to have a safety committee[23] Recent US and
EU regulations that require research on medicines in chil-
dren are expected to foster an increase in the number of
pediatric drug trials in the coming years[24] This calls for
the establishment of standards for trial conduct and
reporting in this field, in which the need for transparency
of the roles of DMCs is an important issue[25]
We undertook a systematic review:
1. to estimate the frequency of reported use of a DMC and
the frequency of reported interim analysis and early stop-
ping in a sample of recent pediatric clinical trials;
2. to assess the quality of the reporting on the various dif-
ferent DMC characteristics and on information about
interim analysis and early termination in these trials.
Methods
A systematic review was conducted using a sample of four
general journals (British Medical Journal,  Journal of the
American Medical Association, Lancet, New England Journal
of Medicine) and four pediatric journals (Archives of Disease
in Childhood, Archives of Pediatric and Adolescent Medicine,
Journal of Pediatrics, Pediatrics), published from January
2005 to December 2007. The included journals have a rel-
evant impact factor in their field, and are known to pub-
lish pediatric trials in a broad range of conditions and age
categories.
Inclusion Criteria
Articles were included when they:
1. reported on a controlled clinical trial, randomized
or quasi-randomized, investigating any type of thera-
peutic intervention (i.e. drug, procedure, behavioral,
health strategy, or other) and including, but not neces-
sarily confined to, participants between 0-18 years;
2. reported on the use of a DMC or interim analysis or
early trial termination.
Literature Search and Study Selection
Two searches were performed by one of the authors (R.F.).
A Medline abstract search was used to identify the total
number of pediatric trials for each journal, in order to
obtain a denominator for frequency calculations. We used
Medline's filters publication type "randomized controlled
trial" and age category "0-18 years", and limited results to
the specific journals and period under study. A separate
full-text search was performed of the eight journals for the
designated period of time using three full-text databases
(HighWire Press, OVID, ScienceDirect). The search strategy
for this full text search was adopted from Sydes et al and
Montori et al[11,15] The resulting list of search terms,
aimed at a high sensitivity, includes variations on terms
related to DMC, interim analysis and early termination.
For general journals, we added terms to identify trials with
participants within the pediatric age range, from previ-
ously validated search strategies[26] The complete list of
terms and the search strategy can be obtained from the
corresponding author.
Titles and abstracts of the full-text search citation results
were screened by one author (R.F.) for eligibility criteria.
Two reviewers (R.F. and J.L.) subsequently screened the
full text articles of included citations independently to
confirm inclusion appropriateness. Any discrepancies
were resolved through discussion until there was consen-
sus. Motives for exclusion were noted and all search
results were kept in database form.
Data Extraction
Information was extracted from each included study
report independently by two authors (R.F., J.L.) using data
collection forms that can be obtained upon request fromBMC Pediatrics 2009, 9:77 http://www.biomedcentral.com/1471-2431/9/77
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the corresponding author. The items included general trial
characteristics, i.e. trial design, funding, centres and set-
ting, details on the disease (based on the International
Classification of Diseases, 10th edition), age of partici-
pants, trial interventions, outcomes, planned and actual
sample size, recruitment, intervention and follow-up
time[27] Risks of bias in terms of substandard random
sequence generation, allocation concealment, blinding
and completeness of outcome data were assessed using
the latest Cochrane Handbook criteria (v5, 2008), and
disagreements were resolved by consensus[28]
There are currently only limited reporting standards for
DMC related activities. Therefore, based on current litera-
ture, we defined a priori a set of parameters for data collec-
tion regarding DMC characteristics, interim analysis and
early termination. For DMC characteristics and interim
analysis, we consulted the book on Data Monitoring
Committees by Ellenberg et al, and the report of the
DAMOCLES group [1,2]. The latter presents empirical evi-
dence and a set of recommendations on various issues
related to DMCs' policies, structure, decision-making and
reporting arrangements[3] We also included the CON-
SORT statement item on interim analysis[19] Early termi-
nation parameters were obtained from recent reviews
addressing the implications of stopping trials early[11,13]
For all three topics there appears to be consensus in the lit-
erature on best practices for some of the parameters, but
many others remain controversial[2,7,12,14,29] Some
items were not reported in the main report of the study,
but in supplementary publications (e.g. online appendix,
design/protocol papers). If these were referred to in the
main paper, we included them in this review.
Data Analysis
We performed a descriptive analysis of collected data,
stratifying results by type of journal (i.e. whether general
or pediatric). All data analyses were performed using SPSS
(version 14; http://www.spss.com).
Results
Search Results and Prevalence of Reporting
Our search using Medline filters identified 648 controlled
trials including pediatric subjects (249 from general jour-
nals and 399 from pediatric journals). The full-text search
for DMC, interim and early termination terms identified a
total of 6,823 potentially relevant records, which were
screened for inclusion criteria. A flow diagram showing
the yield of both searches is shown in Figure 1. Overall
110/648 trials (17%) reported on either, or DMC, interim
analysis, or early termination, and were included in this
review (Table 1 and Figure 2) [30-139] Reporting on these
topics was more frequent in general journals (27%, 68/
249) than in pediatric journals (11%, 42/399). DMCs
were reported in 81% (89/110) of included trials, of
which 52% (46/89) also referred to interim analysis. Of
62/110 (56%) trials that explicitly mentioned interim
analysis, 74% (46/62) also reported use of a DMC. Early
termination of a trial was reported in 32/110 (29%) arti-
cles, of which 21 (66%) reported on a DMC and 22 (69%)
referred to interim analysis.
Trial Characteristics and Risk of Bias
The main characteristics of the included trials are summa-
rized in Table 2. Most studies were designed as parallel,
superiority trials (87%, 96/110). Two-arm, drug treat-
ment studies were predominant (85%, 93/110, and 73%,
80/110, respectively). A placebo group was included in
Table 1: Reporting of Data Monitoring Committees (DMCs) or Interim Analysis or Early Termination: Data on Included Randomized 
Controlled Trials (RCTs), and Total Number of Published RCTs, per Journal, from 2005 to 2007*
Journal RCTs Reporting DMC or Interim/Total RCTs RCTs Reporting Early Termination/Total RCTs
General Journals
BMJ 3/62 (5%) 1/62 (2%)
JAMA 11/24 (46%) 1/24 (4%)
Lancet 23/83 (28%) 9/83 (11%)
N Engl J Med 31/80 (39%) 3/80 (4%)
Total 68/249 (27%) 14/249 (6%)
Pediatric Journals
Arch Dis Child 2/37 (5%) 2/37 (5%)
Arch Ped Adolesc Med 4/61 (7%) 2/61 (3%)
J Pediatr 7/88 (8%) 3/88 (3%)
Pediatrics 24/213 (11%) 11/213 (5%)
Total 37/399 (9%) 18/399 (5%)
*The denominator refers to the total number of pediatric trials for each journal during the studied time period, which was obtained using Medline's 
filters (publication type "randomized controlled trial" and age category "0-18 years").BMC Pediatrics 2009, 9:77 http://www.biomedcentral.com/1471-2431/9/77
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48% (53/110) of trials, while the others used an active
comparator. The majority of trials were multicentre, and
in 80/110 (73%) North American or European/Russian
centres were included. Outcomes included mortality in
51% (56/110) of trials. Studies published in pediatric
journals most frequently included neonates and
addressed neonatal conditions (52%, 22/42), in intensive
care settings (50%, 21/42). The median sample size in
these journals was 136, and 60% (25/42) included less
than 200 participants. The sample sizes included in trials
reported in general journals were substantially larger
(median 601 participants). Studies published in general
journals more frequently included adolescent or adult
participants (51%, 35/68, and 41%, 28/68, respectively),
and the most common diseases under study were infec-
tions (44%, 30/68). Planned sample size calculations
were reported in most trials (84%, 92/110). Where
reported, time to primary outcome was often less than 12
months (81%, 69/85), and the overall median recruit-
ment phase lasted 30 months.
Risk of bias assessments are shown in Table 3. We found
average to high levels of adequacy in all parameters.
Reporting of DMCs and Interim Analysis
DMC nomenclature varied, and we identified 16 different
expressions in use. "Data Safety Monitoring Board" (or
similar, with conjunctions) was the most frequent (58%,
52/89), followed by "Data Safety Monitoring Committee"
(16%, 14/89) and "Data Monitoring Committee" (7%, 6/
89). The terms "external" or "independent" were added in
6% (5/89) and 30% (27/89), respectively. The remaining
expressions included variations on the previously pre-
sented terms ("safety", "monitoring", "committee"), and
the additional keywords "ethics" (n = 3), "monitor", and
"group" (both n = 1). Authors sometimes used different
expressions for DMC in the same paper[39,90,122,127]
In some cases, the nomenclature and lack of additional
information raised doubts as to whether the group in
question was a DMC, particularly when dubious terms
were used (e.g. "consultant") or there was a reference to
other monitoring groups ("ethics", Independent Review
Board, Outcome Adjudication Commit-
tee)[40,57,67,75,107,127] Additionally, in some papers
we identified reports of an apparent role of the DMC in
assessing or verifying outcome diagnoses[111,134]
Flow of citations identified through screening for pediatric trials reporting DMC, interim analysis or early termination Figure 1
Flow of citations identified through screening for pediatric trials reporting DMC, interim analysis or early ter-
mination. Full-text databases search for DMC, interim analysis or early termination and Medline search for controlled pediat-
ric trials, using Medline's filters.
Titles and abstracts 
screened 
386 studies retrieved for  
full text manual screen:  
149 in General Journals 
237 in Pediatric Journals 
110 included studies: 
68 in General Journals 
42 in Pediatric Journals 
6823 citations: 
3114 in General Journals 
3709 in Pediatric Journals 
6437 studies excluded  
(not a controlled trial or not in 
children)
276 studies excluded 
7 not a controlled trial, or no 
children
15 follow-up, pooled or 
post-hoc analysis from 
previous RCTs 
254 no reference to, or 
explicit reporting of no, 
DMC, interim or early 
stop
Full-text screened 
manually 
Medline Search  Full-Text Search 
648 citations: 
249 in General Journals 
399 in Pediatric Journals BMC Pediatrics 2009, 9:77 http://www.biomedcentral.com/1471-2431/9/77
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In most papers DMCs and interim analyses were reported
in the Methods section of the paper (89%, 93/105), some-
times in the Results (20%, 21/105) or in the Discussion
(12%, 13/105) (Table 4). In one paper, interim analyses
themselves were the main results[106] If a DMC was
reported in the Acknowledgements section (66%, 69/
105), the identity of the DMC members was always dis-
closed. In a few papers published in general journals other
sources were referred to for additional details on DMC
and/or interim analysis. These included appendices and
online supplementary material on the journal website,
trial design/protocol papers published in other journals,
or trial or group dedicated web-
sites[44,45,116,117,123,124]
Tables 5 and 6 show the reporting of DMC and interim
analysis parameters in the included papers. The most fre-
quently reported items in each category were the identity
of DMC members (75%, 67/89) and the number of
interim analyses performed (84%, 52/62), respectively.
The affiliation of DMC members was reported infre-
quently (28%, 25/89), as was their independence from
industry sponsors (37%, 33/89). The least reported items
in each category were vigilance of trial conduct parameters
beside safety/efficacy outcome monitoring (19%, 17/89),
and the adjustment of results for interim analysis (31%,
19/62).
No article adequately reported on all DMC parameters,
i.e. members' identity and affiliations, independence,
monitored outcomes, vigilance of other trial conduct
items, blinding to outcome data and existence of prede-
fined stopping guidelines (Table 5). Nine papers (15%)
reported all interim analysis details, i.e. number of analy-
ses planned and performed, parameter defining timing of
these analyses, statistical methods used and outcomes to
which they were applied, and adjustment of results (Table
6). We found two pairs of trials conducted by the same
group of researchers, published in different journals, with
distinct DMC nomenclature and reporting of most param-
eters[73,77,100,119] We also identified some discrepan-
cies between protocols published as supplementary
material and the papers' reports of DMC activities and
interim analysis, e.g. reporting of one but not all statistical
stopping rules [117,124].
Changes in protocol, most often sample size readjust-
ments during the trial, were reported in 18% (20/110).
The DMC was reported to have been involved in these
decisions in 10 (50%) of these trials.
Reporting of Early Terminated Trials
The frequency of reported early terminated trials in this
sample was 21% (14/68) in general journals and 43%
(18/42) in pediatric journals. Four of these trials termi-
nated one or more arms of the trial but proceeded enrol-
ment for the remaining interventions. DMCs and interim
analysis were mentioned in 21/32 (66%) and 22/32
(69%) of early terminated trials, respectively. Reporting of
parameters related to early termination is presented in
Table 7. Only 28% (9/32) papers referred to early trial ter-
mination in the Title or Abstract, and 41% (13/32)
addressed the implications of early termination in the
Discussion section. In five trials (16%) the reason, e.g.
harm, or rationale, e.g. statistical rules, for stopping early
was not clear. Planned sample size was unclear or not
reported in 13% (4/32) of trials, and the majority did not
state predefined stopping guidelines (69%, 22/32). Statis-
tical monitoring methods were not reported in 47%
papers (15/32), while 44% (14/32) did not state the out-
comes under monitoring or analysis. Only five papers
(16%) reported that the final results were adjusted
because of the interim analysis, e.g. by using an alpha
spending approach, four (13%) of which reported all
interim analysis parameters presented in Table 6. Overall,
only two trials (6%) reported all relevant methodological
elements for interpretation of results from early termi-
nated trials, i.e. planned sample size, predefined stopping
guidelines, statistical monitoring methods used, rationale
for early termination, timing of early stop (i.e. whether
Venn diagram summarizing the overlap in reporting on Data  Monitoring Committees, Interim Analysis and Early Termination (n  = 110) Figure 2
Venn diagram summarizing the overlap in reporting 
on Data Monitoring Committees, Interim Analysis and 
Early Termination (n = 110). Number within each circle is 
the total number of articles which reported on these items, 
in isolation or combination.
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Table 2: Characteristics of the 110 Trials Included in this Review, Stratified by Type of Journal
Parameter Pediatric Journals
(n = 42)
General Journals
(n = 68)
Design
Parallel 40 (95) 68 (100)
Cross-Over 2 (5) 0
Factorial Trial 0 7 (10)
Cluster Trial 3 (7) 3 (4)
Noninferiority or Equivalence Trial 4 (10) 8 (12)
Centre†
Multicentre 26 (62) 58 (85)
Participants in more than one country 8 (19) 21 (30)
Funding
Pharma only 10 (24) 15 (22)
Pharma and Institutional 3 (7) 9 (13)
Institutional only 24 (57) 44 (65)
Unclear 5 (12) 0
Participants†
Neonates 23 (55) 17 (25)
Infants/Toddlers (<24 m) 11 (26) 27 (40)
Child (2-11 y) 14 (33) 34 (50)
Adolescents (11-18 y) 9 (24) 35 (51)
Adults 1 (2) 28 (41)
Category of Main Disease*
Neonatal 22 (52) 9 (13)
Endocrine, nutritional and metabolic 6 (14) 3 (4)
Infections 2 (5) 16 (23)
Vaccine trials 3 (7) 14 (20)
Respiratory 3 (7) 7 (10)
Cancer 0 5 (7)
Other 6 (14) 14 (21)
Setting
Outpatient 16 (38) 40 (59)
Inpatient 5 (12) 12 (18)
Intensive Care 21 (50) 16 (23)
Type of Interventions
Drug 24 (57) 56 (82)
Invasive 6 (14) 5 (7)
Other 12 (29) 7 (10)
Number of study groups
2 arms 38 (91) 55 (81)
>2 arms 4 (9) 13 (19)
Use of Placebo or Sham arm 18 (43) 35 (52)
Duration of Intervention
Adequately reported 36 (86) 67 (97)
<1 month 23/36 (64) 35/67 (52)
1-12 months 11/36 (31) 21/67 (31)
>12 months 2/36 (5) 11/67 (17)
Planned Power Calculation 31 (74) 61 (90)
Number of Participants
Median [IQR]# 136 [50-400] 601 [215-2360]
<50 11 (26) 0
50-200 14 (33) 15 (22)
200-1000 9 (21) 25 (37)
>1000 8 (19) 28 (41)
Survival Outcome (primary or secondary) 19 (45) 37 (54)
Time to Primary Outcome
Adequately reported 28 (67) 57 (84)
<1 month 15/28 (54) 15/57 (26)
1-12 months 11/28 (39) 28/57 (49)
>12 months 2/28 (7) 14/57 (25)
Recruitment LengthBMC Pediatrics 2009, 9:77 http://www.biomedcentral.com/1471-2431/9/77
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trial termination was determined by one of the interim
analysis, and which parameter determined the timing of
this interim), whether results were adjusted, and recom-
mendation of DMC.
Discussion
Our study shows that the reporting of parameters related
to DMCs, interim analysis and early termination in pedi-
atric trial reports is heterogeneous and incomplete. This
result is consistent with recent reviews of trials from vari-
ous settings outside child health[8,11,13,15-18] The
CONSORT statement for standards of reporting clinical
trials includes an item on interim analysis, but no details
on DMCs or early termination[19] We propose a minimal
set of reporting parameters that will allow the reader of a
trial report to assess their implications and the validity of
trial results (Table 8). Also, we propose to update the
CONSORT statement accordingly. Below we discuss the
various components of this minimal set of reporting
parameters, as they appear - from our study - to be rele-
vant for the correct design, conduct and reporting of pedi-
atric trials.
Use of DMCs in Pediatric Clinical Trials
In a review of pediatric trials published until 2002, only
2% were found to refer to safety committees[23] Report-
ing of DMCs was more frequent in our - more recent -
sample of pediatric studies, but our results are comparable
to those in other recent reviews covering all age
ranges[15,18] This suggests a recent increased use of
DMCs, but other relevant factors probably account for this
difference. First, bias may have arisen from using a
selected sample of high-impact journals, as reporting of
DMC may differ according to publication practices and
trial results. Second, differences observed between general
and pediatric journals in the current review may be con-
founded, as we can expect trials published in high-impact
general medical journals to have characteristics which are
more frequently associated with the use of a DMC (e.g.
large samples, new interventions).
Deciding whether a clinical trial actually needs a DMC
involves consideration of the safety of the interventions
under study, the type of outcomes, and which population
is included, among other items[1,4,5,7] Regulators rec-
ommend considering DMC involvement in the presence
of vulnerable participants, such as children, but these are
mere recommendations without obligations and no fur-
ther operational guidance is given[4,5] We found that
DMCs are being reported in trials with participants of dif-
ferent age ranges and a wide range of conditions. These
include serious, potentially fatal diseases (e.g. leukemia,
bronchopulmonary dysplasia), but also minor conditions
(e.g. caries, pharyngitis). Pediatric trials most often have
specific ethical, safety and design issues that make a DMC
indispensible, and, therefore, various pediatric specialty
committees recommend their use[24,140-143] Given the
results of this study, we feel there is a need for a standard
in the field of pediatric trials, including operational crite-
ria for the establishment, roles and conduct of DMCs. We
recommend to consider DMCs at least for pediatric trials
concerning serious conditions and in which the recruit-
ment time is long compared to the follow-up time for
individual participants, which makes interim decisions
with consequences for further inclusion possible.
Alternative Terminology
The use of different expressions to denote DMCs may be
attributed to local or national preferences, as well as to
discrepancies in DMC-related guidance documents from
Adequately Reported 35 (83) 65 (96)
Median [IQR] months# 30 [21-38] 29 [22-48]
N (%) unless otherwise stated
†Each category is coded separately, so total may either exceed or not add up to 100%.
*Adapted from the ICD-10 Disease Categories
#IQR: Inter Quartile Range
Table 2: Characteristics of the 110 Trials Included in this Review, Stratified by Type of Journal (Continued)
Table 3: Risk of Bias Assessments of the 110 Trials Included in this Review, Stratified by Type of Journal
Parameter Pediatric Journals
(n = 42)
General Journals
(n = 68)
Risk of Bias†
Adequate Sequence Generation 29 (69) 53 (78)
Adequate Concealment of Allocation 23 (55) 50 (74)
Adequate Blinding of Participants and Providers 21 (50) 34 (50)
Adequate Blinding of Outcome Assessment 25 (60) 53 (78)
Adequate Handling of Missing Data 30 (72) 53 (78)
N (%)
†Each category is coded separately, so total may either exceed or not add up to 100%.BMC Pediatrics 2009, 9:77 http://www.biomedcentral.com/1471-2431/9/77
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various sponsors and institutions[2,7,15] Standardized
nomenclature is necessary in order to distinguish DMCs
from on site monitoring by trial centres, and from other
trial oversight groups (e.g. Institutional Review Boards,
Ethics Committees)[5] It is particularly relevant to recog-
nize each group's distinct and non-overlapping role in
ensuring the validity of the trial[144] To avoid confusion,
we recommend the use of a single expression "Data Mon-
itoring Committee", as suggested by the DAMOCLES
group (see Table 8) [3]
Composition of the DMC
The impact of DMCs' recommendations in trials calls for
transparency and accountability of its members. In our
review DMC members' identities were commonly
reported, but not their affiliations, nor their independ-
ence. Independence is particularly relevant and relates to
real or perceived conflicts of interest of each DMC mem-
ber with regard to the sponsor, the intervention under
study, and the regulator[1,4,5,7]
Three main models for the composition of a DMC have
been proposed previously, with varying degrees of inde-
pendence from the research team and the spon-
sor[1,7,145] First, trials may have an "internal" DMC with
non-independent members, e.g. the principal investiga-
tor, or they may have a monitoring plan without a formal
DMC. A second option is to include only members not
Table 4: Reporting of DMC and Interim Analysis Parameters in trials that mentioned DMCs or Interim Analysis-Section of paper (n = 
105)
Parameter Pediatric Journals
(n = 37)
General Journals
(n = 68)
Section of paper where DMC and/or interim analysis were reported†
Title/Abstract 4 (11) 6 (9)
Introduction 00
Methods 30 (81) 63 (93)
Results 13 (35) 8 (12)
Discussion 6 (16) 7 (10)
Acknowledgements 15 (41) 54 (79)
Online or other papers 0 7 (10)
N (%)
†Does not equal 100%, as some reports/articles contained data in more than one category
Table 5: Reporting of details on DMCs in trials that mentioned DMCs (n = 89)
Parameter Pediatric Journals
(n = 26)
General Journals
(n = 63)
Members Identity
Reported 16 (62) 51 (81)
Unclear or Not Reported 10 (38) 12 (19)
Member Affiliations
Reported 6 (23) 19 (30)
Unclear or Not Reported 20 (77) 44 (70)
Independence
Reported 10 (39) 23 (37)
Unclear or Not Reported 16 (61) 40 (63)
Monitored outcomes
Reported 11 (42) 39 (62)
Unclear or Not Reported 15 (58) 24 (38)
Vigilance of other trial conduct parameters
Reported 5 (9) 12 (19)
Unclear or Not Reported 21 (81) 51 (81)
Blinding to Primary Outcome Data
Reported 7 (27) 18 (29)
Unclear or Not Reported 19 (73) 45 (71)
Predefined Stopping Guidelines
Reported 5 (19) 18 (29)
Unclear or Not Reported 21 (81) 45 (71)
N (%)BMC Pediatrics 2009, 9:77 http://www.biomedcentral.com/1471-2431/9/77
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Table 6: Reporting of Interim Analysis Parameters in trials that mentioned Interim Analysis (n = 62)
Parameter Pediatric Journals
(n = 22)
General Journals
(n = 40)
Number of formal interim analyses planned
Reported 8 (36) 23 (58)
Unclear or Not Reported 14 (64) 17 (42)
Number of formal interim analyses performed
Reported 19 (86) 33 (83)
Unclear or Not Reported 3 (14) 7 (17)
Parameter defining timing of interim
Reported 18 (82) 30 (75)
Unclear or Not Reported 4 (18) 10 (25)
Outcomes on which interim analyses were performed
Reported 13 (59) 32 (80)
Unclear or Not Reported 9 (41) 8 (20)
Statistical monitoring methods specified
Reported 11 (50) 22 (55)
Unclear or Not Reported 11 (50) 18 (45)
Adjustment of results for interim analysis
(p value, CI or estimate)
Reported 2 (9) 17 (43)
Unclear or Not Reported 20 (91) 23 (57)
N (%)
Table 7: Reporting of Early Termination Parameters in Trials Terminated Early (n = 32)†
Parameter Pediatric Journals
(n = 18)
General Journals
(n = 14)
Motive(s) for termination*
Adequately reported 18 (100) 12 (86)
Terminated for efficacy 3 (17) 3 (21)
Terminated for harm 2 (11) 4 (29)
Terminated for futility 3 (17) 4 (29)
Other reasons reported (stand-alone or additional) 13 (72) 2 (14)
Rationale for termination
(i.e. stopping guidelines/rules)
Reported 15 (73) 13 (93)
Unclear or Not Reported 3 (17) 1 (7)
DMC role in early termination
Reported 3 (17) 12 (86)
Unclear or Not Reported 15 (83) 2 (14)
Timing of early termination#
Reported 8 (44) 8 (57)
Unclear or Not Reported 10 (56) 6 (43)
Adjustment of results for interim analysis (p value, CI or estimate)
Reported 2 (11) 8 (57)
Unclear or Not Reported 16 (89) 6 (43)
Section of paper where reference to early termination was reported
Title/Abstract 4 (22) 5 (36)
Methods 14 (78) 14 (100)
Results 13 (72) 6 (43)
Discussion 10 (56) 3 (21)
N (%)
†refers to trials with one or more arms terminated before planned
*Does not equal 100%, as some reports/articles contained data in more than one category
#reporting was considered adequate when it was clear that trial termination was determined by one of the interim analyses, and on which 
parameter the timing of this interim analysis was basedBMC Pediatrics 2009, 9:77 http://www.biomedcentral.com/1471-2431/9/77
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involved in the trial, except for the trial statistician, who
acts as the DMC statistician. Third, all DMC members,
including the statistician, are independent[7] In any case,
appointment and funding by sponsors may affect this
independence[4,5] Knowing how a DMC was established
is paramount for accepting the integrity and for the credi-
bility of this DMC's decisions. Trial reports therefore
should identify members and their affiliations, and dis-
closure of conflicts of interest should be made available.
They should also make a clear statement about their inde-
pendence, possibly with an operational definition (see
Table 8).
Tasks of the DMC, Monitoring and Interim Analysis
Our findings show inadequate reporting on which roles
were taken by a DMC and how they were performed.
Ellenberg et al states that monitoring safety, efficacy and
other trial conduct parameters are among main DMC
activities[1] Activities should be clearly agreed upon and
defined in advance by DMC members, trial sponsors and
investigators, preferably using a "charter"[3]
Outcome data may be monitored in a number of ways,
particularly safety data, which can include either or both
adverse events and other safety/efficacy outcomes[146]
Table 8: Recommendations for a minimal set of parameters to be reported and included in trial registries regarding DMC activities, 
Interim Analysis and Early Stopping† *
Data Monitoring Committees and Interim Analysis*
Terminology
Use of the standard nomenclature "Data Monitoring Committee"
Composition of the DMC
Members' name, affiliation and training
Independence status from research team and sponsor
Tasks of the DMC
Whether the DMC reviewed and accepted the protocol before the start of the trial
Main roles (e.g. monitoring of safety and/or efficacy), and explicit definition of which outcomes where analyzed#
Any additional roles (e.g. monitoring recruitment, quality assurance)
To which outcome(s) was the DMC blinded or unblinded
Interim Analysis and Statistical Monitoring Methods
Whether the protocol included a predefined statistical monitoring plan
Number of planned interim analyses
Timing of planned interim analyses and parameter defining timing 
(i.e. participants or person-time recruitment, number of endpoints, ad hoc time interval)
Type of analysis planned (i.e. efficacy, harm, futility, and/or sample size adjustment), specific statistical methods used (with references and 
uniform terminology), description of boundaries (i.e. their symmetry, p-value/confidence interval, and adjustment, if applicable), and outcome(s) 
to which they were applied (i.e. primary/secondary, any subgroup analysis)
Any formal predefined stopping rules, to which outcome(s) did they apply, and whether they included statistical boundaries and/or other 
considerations
Whether the statistical monitoring plan was completed as planned; if not, which changes were performed, and their rationale
Adjustment for multiple analysis in final results (i.e. reported p-values and/or confidence intervals)
Recommendations to the sponsor/steering committee
DMC recommendation regarding continuation or termination of the trial (with or without adjustments in protocol)
Rationale (i.e. statistical boundaries and/or other considerations)
Whether the sponsor followed the DMC's recommendations
Early terminated trials
Motive(s) for termination (e.g. efficacy, harm, futility, recruitment)
All previously stated items, particularly rationale for early termination (including predefined statistical monitoring plan, type of analysis, 
predefined stopping rules, and DMC recommendation), and adjustment for multiple analysis and early termination in final results
Timing of early termination i.e which of the interim analyses led to trial termination, and on which parameter the timing of this interim analysis 
was based (e.g. number of participants enrolled, predefined number of endpoints)
Planned and final sample size
Total number of events after which the trial was terminated, including definition of these events
Discussion of implications of early termination (i.e. concerning type I and II errors)
Report early termination in the abstract of the paper
†These recommendations are for main reports; further details could be available using other modes of publication (e.g. online appendices, trial 
design/protocol papers, web-based repositories), to which the report should refer to; planned items of this minimal set of parameters should be 
included in prospective trial registries.
*Based on the book by Ellenberg et al, and the report of the DAMOCLES group [1],[2].
#Particularly regarding safety-whether it included adverse events and/or main efficacy outcomes.BMC Pediatrics 2009, 9:77 http://www.biomedcentral.com/1471-2431/9/77
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There is controversy as to the blinding of DMCs[7]
Reporting of these procedural aspects is needed to allow
clinicians to judge decision-making (see Table 8).
We found discrepancies in reporting of the statistical
monitoring plan and the use of interim analysis. Ellenberg
et al highlight the relevance of predefined stopping guide-
lines, including a prudent use of statistical boundaries[1]
Indeed, performing multiple looks at data through
interim analyses without correction can lead to multiplic-
ity problems, with increased risk of type I error[147] A
number of statistical monitoring methods have been
developed to overcome this issue, among which the fre-
quentist, Bayesian and likelihood approaches[2] As each
statistical method has different assumptions and implica-
tions, reporting should be clear and unequivo-
cal[2,10,29,148] Additionally, there are differences
between analyses aimed at efficacy, harm or futility, as
well as the possible use of alternative trial designs (e.g.
adaptive)[149] This is compounded by a nomenclature
which is often inconsistent and overlapping (e.g. "adap-
tive designs" vs. "sample size reviews")[149] Clear report-
ing should allow readers to identify these methods and
their impact of on type I and II error risks (see Table 8).
Early Terminated Trials
We found similar deficiencies in reporting on early termi-
nation as were reported previously in other samples of tri-
als[11,16,17] A significant number of early terminated
trials did not report on the existence of a DMC or on its
role in early stopping. This raises doubts as to which trial
oversight group recommended termination, and whether
this recommendation was issued independently from
sponsor and principal investigators.
Understanding the rationale for early termination is para-
mount to a correct assessment of the validity of trial
results. This implies knowing which, if any, statistical
monitoring methods and stopping rules or guidelines
were used, for which outcome (whether primary or sec-
ondary), and at which stage of the trial[11,13] It may be
relevant in some cases to check if the results were cor-
rected for multiplicity[147] The ongoing controversies
regarding early termination highlight the need for trans-
parent reporting of these items (see Table 8).
Risks of early termination for benefit include implausibly
large treatment effects[11,12,150] Additionally, futility
analyses and protocol changes, like sample size reviews
and adaptive designs, may interfere with the overall power
of the trial[10,148,149] The majority of authors did not
discuss these implications of early termination in their
report. Because readers often base their assessment of a
trial solely on information in the abstract, this should
clearly report early termination and its rationale, as rec-
ommended in the latest CONSORT statement extension
for journal and conference abstracts[151]
Strengths and Limitations of this study
Our full-text search strategy allowed a thorough review of
all published content in the selected journals. This strat-
egy was chosen since the reporting of DMCs, interim anal-
ysis and early termination is not indexed in Medline
records, and it is often not reported in the abstract. We
opted to use Medline's filters to identify pediatric control-
led trials, although we can expect some indexing inaccura-
cies.
We only analyzed published reports, and we did not con-
tact authors to evaluate whether DMC and interim analy-
sis were used but not reported. This will likely lead to an
underestimation of their actual use, as previously
observed with the reporting of other trial methodology
issues[152] Reports of studies in which DMCs had an
active role, particularly when early termination decisions
were taken, may be also more likely to report details on
their activities. A relatively large proportion of trials from
general journals included adult participants. Results from
these trials may not apply to studies that were designed to
include children exclusively, as these trials may differ for
example regarding the presence of a DMC and its tasks
and procedures.
The sample of trials for our review was chosen from recent
volumes to have an estimate of current practice. Most of
these trials were, however, designed, conducted and pub-
lished before the latest standards for DMC use (i.e.
DAMOCLES) were published. We expect that DAMOCLES
will have a future impact on trial design, conduct, and
reporting[3]
There was a moderate to high level of adequacy in the
reporting of risk of bias parameters indicating good adher-
ence to the CONSORT statement on these items. These
results show that there is an apparent shortcoming in the
reporting of DMCs, interim analyses and early termina-
tion, even in trials which appeared well designed and
reported in other aspects. Until CONSORT requires more
information of DMC activities, we expect that reporting
will remain poor. Therefore, we propose to update the
CONSORT statement according to the recommendations
described below.
Recommendations for Reporting of DMC, Interim Analysis 
and Early Termination (Table 8)
We agree with the EQUATOR Group that continued
efforts are needed to improve reporting quality, by updat-
ing and disseminating current standards[153] With the
current increase of clinical trials in child health, and given
our results, we feel this has become urgent in this field. WeBMC Pediatrics 2009, 9:77 http://www.biomedcentral.com/1471-2431/9/77
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propose a list of reporting items on DMC terminology,
composition, tasks, and recommendations, on statistical
monitoring methods and interim analysis, and on early
termination parameters. This could be considered in the
next CONSORT revision. Space limitations should not
preclude transparent reporting, given the current possibil-
ities of online publishing. Discussion should be started on
the inclusion of this minimal set of parameters in design/
protocol papers and trial registries[154,155]
Conclusion
Reporting of DMC activities, interim analysis results and
early termination of pediatric trials is incomplete and het-
erogeneous. New standards for the reporting of these
parameters are necessary in order to evaluate their impact
on the validity of trial results.
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